Tg Therapeutics (TGTX) Net Margin (2016 - 2025)
Historic Net Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 241.74%.
- Tg Therapeutics' Net Margin rose 2371200.0% to 241.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.13%, marking a year-over-year increase of 895600.0%. This contributed to the annual value of 7.11% for FY2024, which is 16800.0% up from last year.
- As of Q3 2025, Tg Therapeutics' Net Margin stood at 241.74%, which was up 2371200.0% from 19.97% recorded in Q2 2025.
- Over the past 5 years, Tg Therapeutics' Net Margin peaked at 241.74% during Q3 2025, and registered a low of 100501.25% during Q4 2022.
- Moreover, its 5-year median value for Net Margin was 296.19% (2023), whereas its average is 9228.68%.
- In the last 5 years, Tg Therapeutics' Net Margin skyrocketed by 2000000000bps in 2021 and then tumbled by -964501500bps in 2022.
- Quarter analysis of 5 years shows Tg Therapeutics' Net Margin stood at 4051.1% in 2021, then tumbled by -2381bps to 100501.25% in 2022, then soared by 100bps to 32.79% in 2023, then soared by 166bps to 21.58% in 2024, then soared by 1020bps to 241.74% in 2025.
- Its Net Margin was 241.74% in Q3 2025, compared to 19.97% in Q2 2025 and 4.19% in Q1 2025.